DelveInsight’s “Becker Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Becker Muscular Dystrophy market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Becker Muscular Dystrophy market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Becker Muscular Dystrophy: An Overview
Becker Muscular Dystrophy (BMD) is an inherited muscle structure disorder that results in the progressive deterioration of limbs and cardiac and skeletal muscles. However, the involuntary muscles are not affected. BMD is a milder version of Duchenne Muscular Dystrophy (DMD). Becker Muscular Dystrophy usually begins in teens or early adulthood, and the course is slower and far less predictable than that of DMD.
Becker Muscular Dystrophy primarily affects males. However, the age of onset and rate of progression can vary. Muscle weakness usually becomes apparent between the ages of 5–15. In some cases, heart involvement (cardiomyopathy) can also be the first sign of BMD. This form of heart disease weakens the cardiac muscle, preventing the heart from pumping blood efficiently.
According to the Genetic and Rare Diseases Information Center, the prevalence of Becker Muscular Dystrophy is estimated to be between 17–27 cases per million people. This means that at a given time, about one in 37,000 to one in 59,000 people live with Becker Muscular Dystrophy.
Becker Muscular Dystrophy Market Key Facts
According to the American Association of Neuromuscular & Electrodiagnostic Medicine, approximately three out of every 100,000 people get affected by Becker Muscular Dystrophy. Additionally, few Becker Muscular Dystrophy patients can live a normal lifespan; however, most die sometime after the age of 40.
In about two-thirds of cases, an affected male inherits the mutation from his mother, who carries a mutated copy of the DMD gene. The other third of cases probably result from new mutations in the gene.
According to the Centers for Disease Control and Prevention (CDC), the estimated prevalence of Duchenne and Becker muscular dystrophy (DBMD) is one in every 7,250 males aged 5–24 years. However, the prevalence of DMD was found to be three times higher than the prevalence of Becker Muscular Dystrophy.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Becker Muscular Dystrophy market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Becker Muscular Dystrophy market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.
Becker Muscular Dystrophy Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders.
The Report Covers the Becker Muscular Dystrophy (BMD) Epidemiology Segmentation by –
Prevalent Cases of BMD
Age-specific Prevalent Cases
Diagnosed and Treatable Cases
Becker Muscular Dystrophy Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Becker Muscular Dystrophy market or expected to get launched during the study period. The analysis covers the Becker Muscular Dystrophy market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Becker Muscular Dystrophy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How Becker Muscular Dystrophy Market Will Evolve by 2032 @
Becker Muscular Dystrophy Therapeutics Analysis
The treatment of Becker Muscular Dystrophy focuses on lessening the symptoms associated with it. There is no cure, but treatments are available to help with symptoms and maximize muscle function. It is vital that a person with BMD stay in shape and continue to use their muscles.
Some of the key players in the Becker Muscular Dystrophy (BMD) Market include:
Becker Muscular Dystrophy (BMD) Therapies covered in the report include:
And many others.
Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Becker Muscular Dystrophy Competitive Intelligence Analysis
4. Becker Muscular Dystrophy Market Overview at a Glance
5. Becker Muscular Dystrophy Disease Background and Overview
6. Becker Muscular Dystrophy Patient Journey
7. Becker Muscular Dystrophy Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Becker Muscular Dystrophy Treatment Algorithm, Current Treatment, and Medical Practices
9. Becker Muscular Dystrophy Unmet Needs
10. Key Endpoints of Becker Muscular Dystrophy Treatment
11. Becker Muscular Dystrophy Marketed Products
12. Becker Muscular Dystrophy Emerging Drugs and Latest Therapeutic Advances
13. Becker Muscular Dystrophy Seven Major Market Analysis
14. Attribute Analysis
15. Becker Muscular Dystrophy Market Outlook (In US, EU5, and Japan)
16. Becker Muscular Dystrophy Access and Reimbursement Overview
17. KOL Views on the Becker Muscular Dystrophy Market
18. Becker Muscular Dystrophy Market Drivers
19. Becker Muscular Dystrophy Market Barriers
21. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report @
Other Trending Healthcare Reports By DelveInsight
“Becker Muscular Dystrophy Pipeline Insights, 2022” report by DelveInsight outlays comprehensive insights into the present clinical development scenario and growth prospects across Becker Muscular Dystrophy (BMD) Market.
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States